查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2020270

癌症诊断市场规模、份额、成长及全球产业分析：按类型、应用和地区划分，并预测至2026-2034年

Cancer Diagnostics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 130 Pages | 商品交期: 请询问到货日

价格

癌症诊断市场成长要素

受癌症负担日益加重、诊断技术不断进步以及各国政府加大早期检测力度等因素的推动，全球癌症诊断市场正经历强劲增长。最新数据显示，2025年该市场规模将达172.4亿美元，预计2026年将达185.1亿美元。到2034年，该市场预计将显着成长至382.7亿美元，2026年至2034年的复合年增长率（CAGR）为9.5%。

市场驱动因素

乳癌、大肠癌和摄护腺癌等癌症发生率的不断上升，是推动有效诊断方法需求成长的主要动力。例如，世界卫生组织（WHO）预测，到2050年，全球新增癌症病例将达到3,500万例，比2022年的2,000万例增加77%。早期准确诊断在降低死亡率方面发挥着至关重要的作用，这加速了包括免疫组织化学（IHC）、原位杂合反应（ISH）、分子诊断和液态生物检体在内的先进诊断技术的应用。

各国政府和私人机构正加强意识提升。例如，美国的「社区大肠直肠癌防治计画」（ACCION）、英国的「肠癌筛检计画」（BCSP）以及世界卫生组织的「全球根除子宫颈癌策略」等项目，旨在扩大筛检和早期疗育的范围。这些倡议透过加速诊断技术的应用，推动了市场成长。

市场限制因素

儘管预计成长前景良好，但诊断程序的高成本和特定风险仍然是挑战。例如，大肠镜检查是大肠直肠癌筛检的黄金标准，但有出血、穿孔和器械相关感染疾病等风险。此外，PCR仪等先进诊断设备的价格在3000美元到30000美元之间，持续的维护成本限制了其普及，尤其是在新兴市场。

市场机会

亚太地区新兴市场正迎来成长机会，这得益于各国政府加大对医疗基础设施的投资以及人们对远端医疗的认知不断提高。新冠疫情加速了远距远端医疗的普及，使得远距癌症筛检和咨询成为可能。预计这一趋势将持续下去，为那些缺乏充足医疗服务的人提供早期诊断和后续观察的机会。

市场趋势

市场参与者越来越关注产品发布、技术进步和伙伴关係。主要趋势包括：

  • 2022 年 6 月：罗氏公司推出“BenchMark ULTRA PLUS”，旨在提高癌症的早期诊断率。
  • 2023 年 10 月：F. Hoffmann-La Roche、Ibex Medical Analytics 和 Amazon Web Services 合作，扩展其人工智慧驱动的前列腺癌和血液恶性肿瘤诊断工具。
  • 2024 年 4 月：美国生技公司 Novelna 开发了一种血液蛋白测试，可以高精度地检测出 18 种早期癌症。
  • 2023 年 5 月：辉瑞和赛默飞世尔科技公司合作，在 30 多个国家/地区改善基于次世代定序(NGS) 的癌症诊断的可及性。
  • 2024 年 4 月：Bio-Rad Laboratories 推出了用于基于生物标记的诊断的 ddPLEX ESR1 突变检测试剂盒。

細項分析

副产品：

  • 预计到 2026 年，检测试剂盒和试剂将推动市场发展，占据 83.07% 的市场份额，这主要得益于诊断测试数量的增加和新产品的推出。
  • 受医疗保健支出不断增长的推动，医疗设备市场预计将稳定成长。

就技术而言：

  • 免疫检测因其在诊断乳癌、前列腺癌和其他癌症方面的有效性而占据市场领先地位。
  • 免疫组化技术有望成为成长最快的技术，这得益于其精准的诊断和治疗预测能力。

按类型：

  • 组织切片检查具有高精度和详细的分子分析能力，预计到 2026 年将主导市场，占据 87.04% 的市场份额。
  • 液态生物检体是成长最快的方法，因为它能快速提供结果（通常比组织切片检查早 26.8 天）。

癌症类型：

  • 乳癌领域仍占据主导地位，反映出全球较高的发生率。
  • 年轻人吸烟率的上升正在推动肺癌市场快速扩张。

按最终用户划分：

  • 由于临床检查室进行的检测数量庞大且拥有先进的设备，因此它们在市场上占据主导地位。
  • 医院和诊所也不断扩张，在同一机构内提供诊断和治疗服务。

区域展望

  • 预计到 2025 年，北美将以 36.81% 的市占率（63.5 亿美元）引领市场，并在 2026 年达到 69 亿美元，这主要得益于 Thermo Fisher Scientific、Abbott、Illumina 和 GE Healthcare 等公司的推动。
  • 预计到 2025 年，欧洲的全球经济规模将达到 52.8 亿美元，到 2026 年将达到 56.3 亿美元，这得益于「10 万基因组计划」等伙伴关係项目和基因组计划的支持。
  • 受中国、日本和印度等国家癌症负担日益加重的推动，亚太地区预计到 2025 年将成长至 37.8 亿美元，到 2026 年将达到 40.7 亿美元。
  • 拉丁美洲、中东和非洲是规模虽小但正在成长的市场，预计到 2025 年，市场规模将分别达到 11.3 亿美元和 6.9 亿美元。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会

第四章：主要考虑因素

  • 2025年主要癌症的盛行率（按国家/地区划分）
  • 主要企业推出新产品
  • 近期产业趋势－併购
  • 主要国家医疗保健成本概览
  • 技术进步、诊断设备和试剂盒
  • 新冠疫情对癌症诊断市场的影响

第五章：2021-2034年全球癌症诊断市场分析、洞察与预测

  • 市场分析、洞察与预测：按产品划分。
    • 装置
    • 检测试剂盒和试剂
  • 市场分析、洞察与预测：按方法论划分
    • 免疫组织化学（IHC）
    • 免疫检测
    • 分子诊断
      • 次世代定序（NGS）
      • 聚合酵素链锁反应（PCR）
      • 原位杂合反应（ISH）
      • 其他的
    • 其他的
  • 市场分析、洞察与预测：按类型
    • 组织切片检查
    • 液态生物检体
  • 市场分析、洞察与预测：按癌症类型划分
    • 肺癌
    • 乳癌
    • 结肠癌
    • 摄护腺癌
    • 其他的
  • 市场分析、洞察与预测：按最终用户划分
    • 医院和诊所
    • 临床检查室
    • 其他的
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美癌症诊断市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲癌症诊断市场分析、洞察与预测（2021-2034年）

  • 国家
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪地那维亚
    • 其他欧洲国家

第八章：亚太地区癌症诊断市场分析、洞察与预测（2021-2034年）

  • 国家
    • 日本
    • 中国
    • 澳洲
    • 印度
    • 东南亚
    • 其他亚太国家

第九章：拉丁美洲癌症诊断市场分析、洞察与预测（2021-2034年）

  • 国家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲癌症诊断市场分析、洞察与预测（2021-2034年）

  • 国家
    • 南非
    • GCC
    • 其他中东和非洲国家

第十一章 竞争分析

  • 全球市占率分析（2025 年）
  • 市场主要企业概览
    • F. Hoffmann-La Roche 有限公司
    • 赛默飞世尔科技
    • 雅培
    • 光明会
    • GE医疗
    • BD
    • bioMerieux SA
    • Myliad Genetics
    • 博雷德实验室
    • QIAGEN
Product Code: FBI110706

Growth Factors of cancer diagnostics Market

The global cancer diagnostics market is witnessing robust growth due to the rising burden of cancer, technological advancements in diagnostics, and increasing government initiatives promoting early detection. According to recent data, the market size was valued at USD 17.24 billion in 2025, and it is projected to reach USD 18.51 billion in 2026. By 2034, the market is expected to expand significantly to USD 38.27 billion, exhibiting a CAGR of 9.5% from 2026 to 2034.

Market Drivers

The increasing prevalence of cancers such as breast, colorectal, and prostate cancer is a primary driver fueling the demand for effective diagnostics. For instance, as per the World Health Organization (WHO), global new cancer cases are projected to reach 35 million by 2050, a 77% increase from 20 million in 2022. Early and precise diagnosis plays a critical role in reducing mortality rates, which has accelerated the adoption of advanced diagnostic solutions, including immunohistochemistry (IHC), in-situ hybridization (ISH), molecular diagnostics, and liquid biopsies.

Government and private organizations have increased initiatives to raise awareness regarding early cancer detection. Programs such as Against Colorectal Cancer in Our Neighborhoods (ACCION) in the U.S., Bowel Cancer Screening Programme (BCSP) in the U.K., and WHO's Global Strategy for Cervical Cancer Elimination aim to expand screening and early intervention efforts. These initiatives are boosting market growth by promoting diagnostic adoption.

Market Restraints

Despite growth, high costs and certain risks associated with diagnostic procedures remain challenges. For example, colonoscopy, a gold standard for colorectal cancer screening, carries risks like bleeding, perforation, and device-associated infections. Additionally, advanced diagnostic instruments such as PCR machines can range from USD 3,000 to USD 30,000, with ongoing maintenance costs, which limits adoption, especially in emerging markets.

Market Opportunities

Emerging markets in Asia Pacific are presenting lucrative opportunities for growth due to increasing government investment in healthcare infrastructure and rising awareness about telemedicine. The COVID-19 pandemic accelerated telemedicine adoption, enabling cancer screening and consultations remotely. This trend is expected to continue, providing access to underserved populations for early diagnosis and follow-ups.

Market Trends

Market players are increasingly focusing on product launches, technological advancements, and partnerships. Notable developments include:

  • June 2022: F. Hoffmann-La Roche Ltd launched BenchMark ULTRA PLUS to enhance timely cancer diagnosis.
  • October 2023: Partnership between F. Hoffmann-La Roche Ltd, Ibex Medical Analytics, and Amazon Web Services to expand AI-powered diagnostic tools for prostate and blood cancers.
  • April 2024: Novelna, a U.S.-based biotech company, developed a blood protein test capable of detecting 18 early-stage cancers with high accuracy.
  • May 2023: Pfizer Inc. and Thermo Fisher Scientific Inc. collaborated to enhance accessibility to NGS-based cancer diagnostics in over 30 countries.
  • April 2024: Bio-Rad Laboratories, Inc. launched the ddPLEX ESR1 Mutation Detection Kit for biomarker-based diagnostics.

Segmentation Analysis

By Product:

  • Assay kits & reagents dominate with 83.07% market share in 2026 due to the increasing number of diagnostic tests and new product launches.
  • Instruments are projected to grow steadily, driven by rising healthcare expenditures.

By Technique:

  • Immunoassays lead the market due to their efficacy in diagnosing breast, prostate, and other cancers.
  • IHC is anticipated to grow fastest, supported by precise diagnosis and treatment prediction capabilities.

By Type:

  • Tissue biopsy dominates with 87.04% market share in 2026, attributed to high accuracy and detailed molecular profiling.
  • Liquid biopsy is growing fastest due to faster result output, often 26.8 days quicker than tissue biopsies.

By Cancer Type:

  • Breast cancer segment remains dominant, reflecting the high global burden.
  • Lung cancer is growing rapidly due to increasing smoking prevalence among youth.

By End-user:

  • Clinical laboratories dominate the market due to high testing volumes and technologically advanced equipment.
  • Hospitals & clinics are also expanding, offering both diagnosis and treatment at the same location.

Regional Outlook

  • North America dominated in 2025 with 36.81% market share (USD 6.35 billion), projected to reach USD 6.9 billion in 2026, driven by companies like Thermo Fisher Scientific, Abbott, Illumina, and GE Healthcare.
  • Europe contributed USD 5.28 billion in 2025, reaching USD 5.63 billion in 2026, supported by partnerships and genome projects like the 100,000 Genomes Project.
  • Asia Pacific grew to USD 3.78 billion in 2025, projected at USD 4.07 billion in 2026, with rising cancer burden in countries like China, Japan, and India.
  • Latin America and Middle East & Africa are smaller but growing markets, valued at USD 1.13 billion and USD 0.69 billion in 2025, respectively.

Competitive Landscape

Key players like F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, Illumina, Inc., GE Healthcare, BD, bioMerieux SA, Myriad Genetics, Inc., Bio-Rad Laboratories, Inc., and QIAGEN dominate the market. Strategic partnerships, product launches, and technological innovations drive growth and expand market access.

Conclusion

The global cancer diagnostics market is poised for strong growth, reaching USD 38.27 billion by 2034. Increasing cancer prevalence, early detection initiatives, technological advancements, and regional expansion in emerging markets are key growth drivers. Despite challenges such as high costs and limited access in some regions, the market continues to evolve with AI integration, biomarker development, and personalized medicine, offering opportunities for improved patient outcomes worldwide.

Segmentation By Product

  • Instruments
  • Assay Kits & Reagents

By Technique

  • Immunohistochemistry (IHC)
  • Immunoassays
  • Molecular Diagnostics
    • Next Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
    • In-situ Hybridization (ISH)
    • Others
  • Others

By Type

  • Tissue Biopsy
  • Liquid Biopsy

By Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others

By End-user

  • Hospitals & Clinics
  • Clinical Laboratories
  • Others

By Region

  • North America (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country)
    • U.S.
    • Canada
  • Europe (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
    • Japan
    • China
    • Australia
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
    • South Africa
    • GCC
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Key Cancer, by Countries/Region in 2025
  • 4.2. New Product Launches by Key Players
  • 4.3. Recent Industry Developments - Mergers & Acquisitions
  • 4.4. Overview of Healthcare Expenditure by Key Countries
  • 4.5. Technological Advancements, Diagnostic Instruments & Kits
  • 4.6. Impact of COVID-19 on the Cancer Diagnostics Market

5. Global Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Instruments
    • 5.1.2. Assay Kits & Reagents
  • 5.2. Market Analysis, Insights and Forecast - By Technique
    • 5.2.1. Immunohistochemistry (IHC)
    • 5.2.2. Immunoassays
    • 5.2.3. Molecular Diagnostics
      • 5.2.3.1. Next Generation Sequencing (NGS)
      • 5.2.3.2. Polymerase Chain Reaction (PCR)
      • 5.2.3.3. In-situ Hybridization (ISH)
      • 5.2.3.4. Others
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Type
    • 5.3.1. Tissue Biopsy
    • 5.3.2. Liquid Biopsy
  • 5.4. Market Analysis, Insights and Forecast - By Cancer Type
    • 5.4.1. Lung Cancer
    • 5.4.2. Breast Cancer
    • 5.4.3. Colorectal Cancer
    • 5.4.4. Prostate Cancer
    • 5.4.5. Others
  • 5.5. Market Analysis, Insights and Forecast - By End User
    • 5.5.1. Hospitals & Clinics
    • 5.5.2. Clinical Laboratories
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Geography
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Instruments
    • 6.1.2. Assay Kits & Reagents
  • 6.2. Market Analysis, Insights and Forecast - By Technique
    • 6.2.1. Immunohistochemistry (IHC)
    • 6.2.2. Immunoassays
    • 6.2.3. Molecular Diagnostics
      • 6.2.3.1. Next Generation Sequencing (NGS)
      • 6.2.3.2. Polymerase Chain Reaction (PCR)
      • 6.2.3.3. In-situ Hybridization (ISH)
      • 6.2.3.4. Others
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Type
    • 6.3.1. Tissue Biopsy
    • 6.3.2. Liquid Biopsy
  • 6.4. Market Analysis, Insights and Forecast - By Cancer Type
    • 6.4.1. Lung Cancer
    • 6.4.2. Breast Cancer
    • 6.4.3. Colorectal Cancer
    • 6.4.4. Prostate Cancer
    • 6.4.5. Others
  • 6.5. Market Analysis, Insights and Forecast - By End User
    • 6.5.1. Hospitals & Clinics
    • 6.5.2. Clinical Laboratories
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Instruments
    • 7.1.2. Assay Kits & Reagents
  • 7.2. Market Analysis, Insights and Forecast - By Technique
    • 7.2.1. Immunohistochemistry (IHC)
    • 7.2.2. Immunoassays
    • 7.2.3. Molecular Diagnostics
      • 7.2.3.1. Next Generation Sequencing (NGS)
      • 7.2.3.2. Polymerase Chain Reaction (PCR)
      • 7.2.3.3. In-situ Hybridization (ISH)
      • 7.2.3.4. Others
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Type
    • 7.3.1. Tissue Biopsy
    • 7.3.2. Liquid Biopsy
  • 7.4. Market Analysis, Insights and Forecast - By Cancer Type
    • 7.4.1. Lung Cancer
    • 7.4.2. Breast Cancer
    • 7.4.3. Colorectal Cancer
    • 7.4.4. Prostate Cancer
    • 7.4.5. Others
  • 7.5. Market Analysis, Insights and Forecast - By End User
    • 7.5.1. Hospitals & Clinics
    • 7.5.2. Clinical Laboratories
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Spain
    • 7.6.5. Italy
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Instruments
    • 8.1.2. Assay Kits & Reagents
  • 8.2. Market Analysis, Insights and Forecast - By Technique
    • 8.2.1. Immunohistochemistry (IHC)
    • 8.2.2. Immunoassays
    • 8.2.3. Molecular Diagnostics
      • 8.2.3.1. Next Generation Sequencing (NGS)
      • 8.2.3.2. Polymerase Chain Reaction (PCR)
      • 8.2.3.3. In-situ Hybridization (ISH)
      • 8.2.3.4. Others
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Type
    • 8.3.1. Tissue Biopsy
    • 8.3.2. Liquid Biopsy
  • 8.4. Market Analysis, Insights and Forecast - By Cancer Type
    • 8.4.1. Lung Cancer
    • 8.4.2. Breast Cancer
    • 8.4.3. Colorectal Cancer
    • 8.4.4. Prostate Cancer
    • 8.4.5. Others
  • 8.5. Market Analysis, Insights and Forecast - By End User
    • 8.5.1. Hospitals & Clinics
    • 8.5.2. Clinical Laboratories
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. Australia
    • 8.6.4. India
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Instruments
    • 9.1.2. Assay Kits & Reagents
  • 9.2. Market Analysis, Insights and Forecast - By Technique
    • 9.2.1. Immunohistochemistry (IHC)
    • 9.2.2. Immunoassays
    • 9.2.3. Molecular Diagnostics
      • 9.2.3.1. Next Generation Sequencing (NGS)
      • 9.2.3.2. Polymerase Chain Reaction (PCR)
      • 9.2.3.3. In-situ Hybridization (ISH)
      • 9.2.3.4. Others
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Type
    • 9.3.1. Tissue Biopsy
    • 9.3.2. Liquid Biopsy
  • 9.4. Market Analysis, Insights and Forecast - By Cancer Type
    • 9.4.1. Lung Cancer
    • 9.4.2. Breast Cancer
    • 9.4.3. Colorectal Cancer
    • 9.4.4. Prostate Cancer
    • 9.4.5. Others
  • 9.5. Market Analysis, Insights and Forecast - By End User
    • 9.5.1. Hospitals & Clinics
    • 9.5.2. Clinical Laboratories
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Instruments
    • 10.1.2. Assay Kits & Reagents
  • 10.2. Market Analysis, Insights and Forecast - By Technique
    • 10.2.1. Immunohistochemistry (IHC)
    • 10.2.2. Immunoassays
    • 10.2.3. Molecular Diagnostics
      • 10.2.3.1. Next Generation Sequencing (NGS)
      • 10.2.3.2. Polymerase Chain Reaction (PCR)
      • 10.2.3.3. In-situ Hybridization (ISH)
      • 10.2.3.4. Others
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Type
    • 10.3.1. Tissue Biopsy
    • 10.3.2. Liquid Biopsy
  • 10.4. Market Analysis, Insights and Forecast - By Cancer Type
    • 10.4.1. Lung Cancer
    • 10.4.2. Breast Cancer
    • 10.4.3. Colorectal Cancer
    • 10.4.4. Prostate Cancer
    • 10.4.5. Others
  • 10.5. Market Analysis, Insights and Forecast - By End User
    • 10.5.1. Hospitals & Clinics
    • 10.5.2. Clinical Laboratories
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.6.1. South Africa
    • 10.6.2. GCC
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Profiles of Players Operating in the Market
    • 11.2.1. F. Hoffmann-La Roche Ltd
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Thermo Fisher Scientific Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Abbott
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Illumina, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. GE Healthcare
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. BD
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. bioMerieux SA
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Myriad Genetics, Inc
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bio-Rad Laboratories, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. QIAGEN
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 3: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 4: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 5: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 6: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 7: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 8: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 9: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 10: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 11: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 12: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 13: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 14: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 15: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 16: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 17: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 18: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 19: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 20: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 21: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 22: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 23: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 24: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 25: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 26: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 27: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 28: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 29: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 30: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 31: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 32: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 33: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 34: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 35: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 37: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 38: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 39: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 40: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 41: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 42: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cancer Diagnostics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cancer Diagnostics Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Cancer Diagnostics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 4: Global Cancer Diagnostics Market Value Share (%), by Type, 2025 & 2034
  • Figure 5: Global Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025 & 2034
  • Figure 6: Global Cancer Diagnostics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 7: Global Cancer Diagnostics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 8: North America Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 9: North America Cancer Diagnostics Market Value Share (%), by Product, 2025
  • Figure 10: North America Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 11: North America Cancer Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 12: North America Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 13: North America Cancer Diagnostics Market Value Share (%), by Type, 2025
  • Figure 14: North America Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 15: North America Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
  • Figure 16: North America Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 17: North America Cancer Diagnostics Market Value Share (%), by End-user, 2025
  • Figure 18: North America Cancer Diagnostics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Cancer Diagnostics Market Value Share (%), By Country, 2025
  • Figure 20: Europe Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 21: Europe Cancer Diagnostics Market Value Share (%), by Product, 2025
  • Figure 22: Europe Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 23: Europe Cancer Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 24: Europe Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 25: Europe Cancer Diagnostics Market Value Share (%), by Type, 2025
  • Figure 26: Europe Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 27: Europe Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
  • Figure 28: Europe Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 29: Europe Cancer Diagnostics Market Value Share (%), by End-user, 2025
  • Figure 30: Europe Cancer Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Cancer Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 33: Asia Pacific Cancer Diagnostics Market Value Share (%), by Product, 2025
  • Figure 34: Asia Pacific Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 35: Asia Pacific Cancer Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 36: Asia Pacific Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 37: Asia Pacific Cancer Diagnostics Market Value Share (%), by Type, 2025
  • Figure 38: Asia Pacific Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 39: Asia Pacific Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
  • Figure 40: Asia Pacific Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 41: Asia Pacific Cancer Diagnostics Market Value Share (%), by End-user, 2025
  • Figure 42: Asia Pacific Cancer Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Cancer Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 45: Latin America Cancer Diagnostics Market Value Share (%), by Product, 2025
  • Figure 46: Latin America Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 47: Latin America Cancer Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 48: Latin America Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 49: Latin America Cancer Diagnostics Market Value Share (%), by Type, 2025
  • Figure 50: Latin America Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 51: Latin America Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
  • Figure 52: Latin America Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 53: Latin America Cancer Diagnostics Market Value Share (%), by End-user, 2025
  • Figure 54: Latin America Cancer Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Cancer Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 57: Middle East & Africa Cancer Diagnostics Market Value Share (%), by Product, 2025
  • Figure 58: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 59: Middle East & Africa Cancer Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 60: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 61: Middle East & Africa Cancer Diagnostics Market Value Share (%), by Type, 2025
  • Figure 62: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 63: Middle East & Africa Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
  • Figure 64: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 65: Middle East & Africa Cancer Diagnostics Market Value Share (%), by End-user, 2025
  • Figure 66: Middle East & Africa Cancer Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Cancer Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Cancer Diagnostics Market Share (%), By Company, 2025